2022
Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2015
Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy.
Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.Peer-Reviewed Original ResearchCAPRA scoreActive surveillanceProstate cancerAdverse pathologyBiopsy GleasonProstate cancer active surveillanceIntermediate-risk prostate cancerProstate Risk Assessment (CAPRA) scoreRisk categoriesMultivariate logistic regression modelAdverse surgical pathologyRisk prostate cancerAdverse pathological outcomesRisk assessment scoreLogistic regression modelsBiopsy upgradeGleason upgradeSurveillance biopsiesMedian ageRepeat biopsyInitial diagnosisSubsequent biopsyRadical prostatectomyMedian changeSurgical pathology